


# Could radiomic signature developed from NSCLC patients predict overall survival of patients with ALK+ mutation?

Lyu Huang\*, Min Fan, Weigang Hu, Jiazhou Wang, Jiayan Chen, Xinyan Xu, Jiayu Lu, Gan Qing

Fudan University Shanghai Cancer Center, Shanghai, China



- 1 Features with ICC value larger than 0.9 were considered as stable in test-retest.
- 2 The radiomic signature was developed in NSCLC Radiomic Collection by using the LASSO Cox regression model and leave-one-out cross-validation
- 3 The radiomic signature was tested to investigate for translational capability among NSCLC and ALK-positive patients.




Figure 3. The stratified analysis results in all datasets.

**Highlights**

We found that radiomic signature developed in NSCLC patients are applicable to ALK-positive patients in non-targeted therapy group.

We also found that when signature was applied to those received TKI, it can't make a fair prediction, which indicates that the radiomic signature's translational capability might be limited and restricted to patients received a similar type of therapy.

**Info.**

Abstract ID: 40294  
**Session Title: Quantitative Imaging: Translation to Practice**  
**Date and Time: 07/31/2018 | 7:30AM — 9:30AM**  
 Presenting Author: Lyu Huang

Methods